271 results match your criteria: "Institute for Clinical Effectiveness and Health Policy (IECS)[Affiliation]"
Cochrane Database Syst Rev
December 2024
NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK.
Background: Sample collection is a key driver of accuracy in the diagnosis of SARS-CoV-2 infection. Viral load may vary at different anatomical sampling sites and accuracy may be compromised by difficulties obtaining specimens and the expertise of the person taking the sample. It is important to optimise sampling accuracy within cost, safety and accessibility constraints.
View Article and Find Full Text PDFInt J Technol Assess Health Care
December 2024
Department of Public Health, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
Context: Healthcare stakeholders in Latin America, including payers, manufacturers, and patients, seek to expedite access to technologies. However, uncertainty sometimes surrounds their true benefits and budgetary implications. Managed entry agreements (MEAs) are proposed to address this uncertainty by redistributing risks among key actors.
View Article and Find Full Text PDFJ Mark Access Health Policy
December 2024
The National Authority for Assessment and Accreditation in Healthcare (INEAS), Tunis 1002, Tunisia; (N.H.).
The Tunisian Health Technology Assessment (HTA) body, INEAS, conducted a cost-effectiveness analysis (CEA) of vemurafenib in the treatment of locally advanced or metastatic BRAF V600-mutated melanoma. The objective of this analysis was to enable the use of value-based pricing as a new approach to price negotiation. This study was part of a broader HTA report that was prepared in response to a joint request from the regulatory authorities and the CNAM, Tunisia's compulsory insurance scheme.
View Article and Find Full Text PDFJ Pain Symptom Manage
February 2025
Center for Research and Implementation in Palliative Care (M.L.R.), Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.
Background: Research on concurrent parent and patient-reported outcomes has primarily focused on reaching agreement. However, little is known about how to interpret and address discrepancies, which are not uncommon, between both viewpoints.
Objectives: To explore parents' perspectives on reporting about child symptoms and quality of life (QoL) concurrently with their child in the context of pediatric advanced cancer.
Cochrane Database Syst Rev
October 2024
Department of Applied Health Sciences, School of Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Gac Sanit
December 2024
Group of Evaluation of Health Determinants and Health Policies, Department of Basic Sciences, Universitat Internacional de Catalunya, Sant Cugat del Vallès, Barcelona, Spain; Centro de estudios del uso saludable de pantallas durante la Infancia (Kenko Lab), Spain; Group of Evaluation of Health Determinants and Health Policies, Centro Universitario de Mérida, Universidad de Extremadura, Badajoz, Spain.
Objective: To explore the use of smartphones at mealtimes by children in fast food restaurants in the city of Barcelona and to assess the variables associated with this use.
Method: A cross-sectional study was carried out. Data from 1616 children of estimated ages between 4 to 10 years were collected in fast-food restaurants in the ten districts of Barcelona between October 2021 and July 2022.
Value Health Reg Issues
November 2024
Value Evidence Outcome Department, GlaxoSmithKline, Wavre, Belgium.
Objectives: Herpes zoster (HZ) substantially affects patients' health-related quality of life (HRQoL), both in the acute phase and also in those developing postherpetic neuralgia (PHN). Building upon a previous qualitative concept elicitation study in Canada, we adopted a similar approach to further understand the patient experience of HZ/PHN in Argentina and impact on quality of life and qualitatively validate the previously published conceptual model for Argentina.
Methods: (1) Comprehensive literature review of HZ impact on HRQoL in Latin America.
Expert Rev Pharmacoecon Outcomes Res
January 2025
Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.
Objectives: Our study assessed the budget impact and cost per responder of upadacitinib15mg and 30 mg for moderate to severe atopic dermatitis (MS-AD) treatment from social security and private health sector perspective in Argentina.
Methods: A budget impact model was adapted to depict clinical and economic aspects of treatment over a 5-years horizon time. Scenario analyses and deterministic sensitivity analyses were performed.
Health Policy Plan
October 2024
Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS)-CIESP-CONICET, Ravignani 2024, Buenos Aires, CABA 1414, Argentina.
Despite being the most cost-effective tobacco control policy, tobacco taxation is the least implemented component of the World Health Organization MPOWER package to reduce smoking worldwide. In Mexico, both smoking prevalence and taxation have remained stable for more than a decade. This study aims to provide evidence about the potential effects of taxation to reduce the burden of tobacco-related diseases and the main attributable social costs in Mexico, including informal (unpaid) care costs, which are frequently ignored.
View Article and Find Full Text PDFDisabil Rehabil
July 2024
Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.
Purpose: To examine the burden of treatment (BoT) experienced by people with Amyotrophic Lateral Sclerosis (ALS) in Argentina.
Methods: Qualitative methodological design based on semi-structured interviews. Nineteen semi-structured interviews were conducted (PwALS = 7, informal caregivers= 12).
Drug Saf
October 2024
School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA.
Background: Pregnant persons are susceptible to significant complications following COVID-19, even death. However, worldwide COVID-19 vaccination coverage during pregnancy remains suboptimal.
Objective: This study assessed the safety and effectiveness of COVID-19 vaccines administered to pregnant persons and shared this evidence via an interactive online website.
Pharmacoecon Open
September 2024
Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Doctor Emilio Ravignani, 2024, Buenos Aires, Argentina.
Objectives: The aim of this study was to perform a budget impact analysis (BIA) of introducing olaparib treatment for adult patients with metastatic castration-resistant prostate cancer in Argentina.
Methods: A BIA model was used to estimate the cost difference between the current scenario (without olaparib) and the new scenario (incorporation of olaparib) for a third-party payer over a 5-year time horizon. The budgetary impact is estimated at the national health system level and by healthcare sectors in Argentina.
Midwifery
July 2024
Departament Obstetrics and Puericulture, Medicine Faculty, Universidad de Concepción, Casilla 160-C, Chile. Electronic address:
BJOG
August 2024
Department of Obstetrics and Gynaecology, University of Calabar Teaching Hospital, Calabar, Nigeria.
Objective: To determine the incidence, risk factors and outcomes of babies with neonatal jaundice in a network of referral-level hospitals in Nigeria.
Design: A cross-sectional analysis of perinatal data collected over a 1-year period.
Setting: Fifty-four referral-level hospitals (48 public and 6 private) across the six geopolitical zones of Nigeria.
Pharmacoecon Open
July 2024
Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Doctor Emilio Ravignani 2024, Buenos Aires, Argentina.
Objectives: To perform a budget impact analysis (BIA) of introducing olaparib as maintenance therapy in women who have BRCA mutations (BRCAm) with platinum-sensitive recurrent ovarian cancer (PSROC) in combination with bevacizumab in Argentina.
Methods: A BIA model was used to analyse over a 5-year time horizon the change in the health system's budget following the adoption of olaparib as maintenance therapy in BRCAm patients with PSROC. The BIA for each year was estimated by comparing the cost difference between the current scenario (treatment with bevacizumab) and the new scenario (the addition of olaparib) for a third-party payer.
Rev Peru Med Exp Salud Publica
May 2024
Instituto de Efectividad Clínica y Sanitaria, Buenos Aires, Argentina.
Objective.: Motivation for the study. Treatment options for HER2-positive breast cancer were evaluated, focusing on the efficacy and safety of trastuzumab-emtansine (T-DM1) compared to other anti-HER2 therapies.
View Article and Find Full Text PDFPublic Health
July 2024
Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina. Electronic address:
Objectives: Lung cancer remains a significant global public health challenge and is still one of the leading causes of cancer-related death in Argentina. This study aims to assess the disease and economic burden of lung cancer in the country.
Study Design: Burden of disease study.
Cochrane Database Syst Rev
May 2024
Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET), Buenos Aires, Argentina.
Background: Obesity is a major health problem worldwide as it can lead to high blood pressure, heart disease, stroke, diabetes, and insulin resistance. The prevalence of overweight and obesity is increasing worldwide across different age groups. There is evidence of an inverse relationship between calcium intake and body weight.
View Article and Find Full Text PDFFront Pediatr
March 2024
Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Ciudad Autónoma de Buenos Aires, Argentina.
Background: Limited data are available on the clinical impact and economic burden of COVID-19 in the pediatric population in Argentina. We aimed to estimate the disease and economic burden of COVID-19 on children and adolescents.
Methods: We analyzed official national databases and conducted a supplemental systematic review of the published literature with meta-analysis in children aged 0-18.
BJOG
August 2024
Department of Obstetrics and Gynaecology, Nnamdi Azikiwe University, Faculty of Medicine, Nnewi Campus, Anambra State, Nigeria.
Objective: To examine the prevalence, perinatal outcomes and factors associated with neonatal sepsis in referral-level facilities across Nigeria.
Design: Secondary analysis of data from the Maternal and Perinatal Database for Quality, Equity and Dignity Programme in 54 referral-level hospitals across Nigeria.
Setting: Records covering the period from 1 September 2019 to 31 August 2020.
BJOG
August 2024
Department of Obstetrics & Gynaecology, University of Ilorin/University of Ilorin Teaching Hospital, Ilorin, Nigeria.
Objective: To describe the outcomes and quality of care for women and their babies after caesarean section (CS) in Nigerian referral-level hospitals.
Design: Secondary analysis of a nationwide cross-sectional study.
Setting: Fifty-four referral-level hospitals.
BJOG
August 2024
Department of Obstetrics and Gynaecology, Aminu Kano Teaching Hospital, Kano, Nigeria.
Objective: To determine the incidence and sociodemographic and clinical risk factors associated with birth asphyxia and the immediate neonatal outcomes of birth asphyxia in Nigeria.
Design: Secondary analysis of data from the Maternal and Perinatal Database for Quality, Equity and Dignity Programme.
Setting: Fifty-four consenting referral-level hospitals (48 public and six private) across the six geopolitical zones of Nigeria.
Implement Sci Commun
March 2024
INCAP Research Center for the Prevention of Chronic Diseases (CIIPEC), Institute of Nutrition of Central America and Panama (INCAP), Guatemala City, Guatemala.